SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (4280)3/9/1998 1:27:00 PM
From: scaram(o)uche  Read Replies (1) of 9719
 
PB:

Patient-specific therapies have always bombed. However, I am intrigued by the recent Stanford (Levy)/Vical license for anti-id in B lymphoma (similar to the early projects that almost took Idec down the drain). Note, also, that Levy's lab is doing the most advanced work with adjuvancy for DNA vaccines.

Your brief analysis nails Vical..... very accurate and, IMO, insightful. There's plenty of time left for a decision.

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News